These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11517739)

  • 1. [Double-blind trial of the effectiveness of antibodies to interferon-gamma and tumor necrosis factor-alpha in rheumatoid arthritis (preliminary results)].
    Lukina GV; Sigidin IaA; Skurkovich SV; Skurkovich BS
    Ter Arkh; 2001; 73(5):12-5. PubMed ID: 11517739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neutralisation of interferon gamma--a new trend in therapy of rheumatoid arthritis].
    Nasonova VA; Lukina GV; Sigidin IaA
    Ter Arkh; 2008; 80(5):30-7. PubMed ID: 18590111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New approaches to biological immunomodulation therapy of rheumatoid arthritis: neutralization of basic cytokines].
    Lukina GV; Sigidin IaA; Skurkovich SV; Skurkovich BS
    Ter Arkh; 1998; 70(5):32-7. PubMed ID: 9644739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, open-label, comparative, 6-month trial of oral ultra-low doses of antibodies to tumor necrosis factor-alpha and diclofenac in rheumatoid arthritis.
    Dugina JL; Petrov VI; Babayeva AR; Martyushev-Poklad AV; Tcherevkova EV; Epstein OI; Sergeeva SA
    Int J Tissue React; 2005; 27(1):15-21. PubMed ID: 15847101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study.
    Genevay S; Finckh A; Ciurea A; Chamot AM; Kyburz D; Gabay C;
    Arthritis Rheum; 2007 May; 57(4):679-85. PubMed ID: 17471545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis.
    Sokka T; Pincus T
    Arthritis Rheum; 2003 Feb; 48(2):313-8. PubMed ID: 12571838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
    Tijhuis GJ; van de Putte LB; Breedveld FC
    Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
    Bokarewa M; Lindholm C; Zendjanchi K; Nadali M; Tarkowski A
    Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression.
    Netea MG; Radstake T; Joosten LA; van der Meer JW; Barrera P; Kullberg BJ
    Arthritis Rheum; 2003 Jul; 48(7):1853-7. PubMed ID: 12847679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F; Michaud K
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis.
    Furst DE; Weisman M; Paulus HE; Bulpitt K; Weinblatt M; Polisson R; Zaug M; Kneer J; Van der Auwera P; Stevens RM
    J Rheumatol; 2003 Oct; 30(10):2123-6. PubMed ID: 14528504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel predictor of clinical response to methotrexate in patients with rheumatoid arthritis: a pilot study of in vitro T cell cytokine suppression.
    Haroon N; Srivastava R; Misra R; Aggarwal A
    J Rheumatol; 2008 Jun; 35(6):975-8. PubMed ID: 18464312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
    Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA
    Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
    Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM;
    J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Infliximab in aggressive and refractory rheumatoid arthritis. A pilot study].
    Caramaschi P; Canestrini S; Biasi D; Carletto A; Scambi C; Scarperi A; Bambara LM
    Recenti Prog Med; 2002 Jan; 93(1):19-24. PubMed ID: 11850995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological therapies for rheumatoid arthritis.
    Edwards CJ
    Br Med Bull; 2005; 73-74():71-82. PubMed ID: 16174791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study.
    Yee CS; Filer A; Pace A; Douglas K; Situnayake D; Rowe IF;
    Rheumatology (Oxford); 2003 Jul; 42(7):856-9. PubMed ID: 12730544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.